ASM Leads Support Letter for House Tracking Pathogens Act
ASM and partner organizations expressed support for H.R. 7152, introduced by Rep. Ami Bera and Rep. Scott Peters.
Join ASM in urging Congress to bolster funding to $175 million per year for the AMD program.
This 2016 Academy report provides suggestions for combating current limitations of NGS-based diagnostic tests in clinical settings.
What is Next-Gen Sequencing and AMD?
DNA sequencing establishes the order of the bases that make up the genetic code of an organism. Next-generation DNA sequencing (NGS) refers to the use of technologies for sequencing DNA that became available shortly after the completion of the Human Genome Project. The CDC's AMD program harnesses the power of next-generation genomic sequencing, high-performance computing and epidemiology to study pathogens.
ASM' Advocates for Next-Gen Sequencing
Working With Congress
- ASM Leads Support Letter for House Tracking Pathogens Act
- ASM Praises Inclusion of Tracking Pathogens Act in Draft Legislation
- ASM and Stakeholders Endorse Tracking COVID-19 Variants Act
- ASM Urges Congress to Invest $40 Million in CDC AMD Program
- ASM and Partners Request $60M for AMD Program at CDC
Working with CDC
Feb 2021 Update
June 2020 Update
With $1.7 billion in multi-year funding from the American Rescue Plan Act of 2021, the AMD program is supporting state, local and territorial public health laboratories with more staff and resources to collect specimens for COVID-19 testing, sequence them to identify and track SARS-CoV-2 variants and share data. In addition to the current investments in state and local jurisdictions included in the data below, CDC has been supporting national SARS-CoV-2 sequencing capacity through contracts with large commercial diagnostic laboratories, which have received over $240 million to sequence specimens from across the United States.
Why Invest in Genomic Sequencing?
Significantly boosting U.S. genetic surveillance and viral sequencing is key to moving beyond the current COVID-19 pandemic and effectively responding to future challenges, not only associated with novel and evolving infectious diseases, but also seasonal threats, antimicrobial resistance and food borne pathogens.
SARS-CoV-2 Sequencing Data: The Devil Is in the Genomic Detail
The study of SARS-CoV-2 whole genome sequencing data has led to many important findings about this virus, and we will need more sequence data from samples from all over the world in order to come up with effective approaches to control and prevent COVID-19 infections.
Whole Genome Sequencing as a Tool for Hospital Surveillance
Whole genome sequencing has been beneficial for identifying outbreaks and performing public health surveillance. The precise and detailed data that this technology provides can be especially beneficial to infection prevention efforts in the hospital setting.
Hear From Experts
Dr. Joe DeRisi talks about how genomics helped solve the mystery of dying leopard sharks in San Francisco bay, how a “virochip” array helped identify the SARS virus, how genomics can help identify unknown causes of encephalitis, how the sewer may hold the key to predicting infectious disease outbreaks and how computational capabilities represent the current bottleneck to global benefit from genomics technologies.
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia and increased Ct values after administration of mRNA vaccine.
Next generation sequencing (NGS) to identify the etiology of infectious disease has the potential to assist physicians in provided faster, pathogen-targeted antimicrobial therapy. ASM hosted a symposium on clinical metagenomics for infectious disease at World Microbe Forum 2021.
Network with Experts
The ASM Conference on Rapid Applied Microbial Next-Generation Sequencing and Bioinformatic Pipelines taking place October 2022 in Baltimore, Md. will feature leading experts on topics including sequencing in clinical and public health microbiology, bioinformatic tools, data integration and more.
CDC Advanced Molecular Detection Program
Pathogen AMD Database
The SPHERES consortium aligns federal laboratories and public health agencies with international genomics efforts and engages the private sector in efforts to better understand the genomics and patterns of SARS-CoV-2 transmission across the United States.
PulseNet compares the DNA fingerprints of bacteria from patients to find clusters of disease that represent unrecognized outbreaks.